Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Jul 8, 2024 · CIK: 1581178
Sentiment: neutral
Topics: reporting, foreign-issuer, press-release
TL;DR
Eupraxia Pharmaceuticals filed a 6-K, check Exhibit 99.1 for news.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on July 8, 2024, reporting for the month of July 2024. The filing includes Exhibit 99.1, a press release dated July 8, 2024. The company is incorporated in Canada and its principal executive offices are located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' reporting status and includes a press release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This filing is a routine report and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Numbers
- 001-41923 — SEC File Number (Identifies the company's filing history with the SEC.)
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Filer
- July 8, 2024 (date) — Filing date and press release date
- Bruce Cousins (person) — Signatory for the filing
- 201-2067 Cadboro Bay Rd. Victoria, British Columbia, Canada V8R 5G4 (address) — Principal executive offices
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have filed or are required to file with a stock exchange.
What is included as part of this specific 6-K report?
This report includes Exhibit 99.1, which is a Press Release dated July 8, 2024.
Where are Eupraxia Pharmaceuticals Inc.'s principal executive offices located?
The company's principal executive offices are located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Who signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
The form was signed by Bruce Cousins, who is duly authorized.
Does Eupraxia Pharmaceuticals Inc. file annual reports under Form 20-F or Form 40-F?
Eupraxia Pharmaceuticals Inc. files annual reports under Form 40-F.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.4 · Accepted 2024-07-08 07:01:30
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 15KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-000857.txt ( ) — 59KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: July 8, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer